EUVIMEDEUVIMED entdecken
Crossref

Consolidative Hypofractionated Radiotherapy for Oligometastatic Non–Small-Cell Lung Cancer

Jongmoo Park, Min Kyu Kang, Shin Yup Lee, Seung Soo Yoo, Sun Ha Choi, Jae Yong Park, Young Woo Do, Eung Bae Lee, Shin Young Jeong, Moonsik Kim, Bong Kyung Bae

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.08.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Jongmoo Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Dose Hypofractionation. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Local consolidative therapy (LCT) has emerged as a widely recognized treatment strategy for patients with oligometastatic non-small-cell lung cancer (NSCLC), but clinical trial populations often do not reflect real-world complexities. This study evaluated the efficacy and safety of consolidative hypofractionated radiotherapy in a routine clinical cohort. METHODS: We retrospectively reviewed 216 patients with oligometastatic NSCLC treated with consolidative hypofractionated radiotherapy (biologically effective dose [BED] ≥ 50 Gy, < 10 fractions) between 2013 and 2024. Outcomes included local control (LC), progression-free survival (PFS), overall survival (OS), and toxicity. Patients were classified as having "genuine" or "induced" oligometastatic disease (OMD) according to ESTRO/EORTC criteria. RESULTS: The median patient age was 73 years. At a median follow-up of 1.8 years, the 1-year LC, PFS, and OS rates were 88.7%, 51.2%, and 79.7%, respectively. Median PFS was 1.0 year and median OS was 2.6 years. In multivariable analysis, "induced" OMD was an independent predictor of worse LC (hazard ratio [HR], 2.546, P = .001) and PFS (HR, 1.863, P < .001) compared to "genuine" OMD. Radiotherapy parameters, including gross tumor volume and BED, were not significantly associated with survival outcomes. Grade 3 radiation pneumonitis occurred in 1.8% of patients; no grade 4-5 toxicities were observed. CONCLUSIONS: Consolidative hypofractionated radiotherapy is safe and effective for patients with oligometastatic NSCLC, including elderly patients. The OMD classification system provides superior prognostic value over technical radiotherapy parameters, suggesting that treatment strategies should be tailored to the biological trajectory of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiation Dose HypofractionationHumansFemaleMaleRetrospective StudiesAgedAged, 80 and overMiddle AgedPrognosisSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

ElderlyNon-small-cell lung cancerOligometastasisProgression-free survivalRadiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Department of Thoracic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Korea. Electronic address: bae8808@knu.ac.kr.

Zitieren

APA

Park, J., Kang, M. K., Lee, S. Y., Yoo, S. S., Choi, S. H., Park, J. Y., Do, Y. W., Lee, E. B., Jeong, S. Y., Kim, M., & Bae, B. K. (2026). Consolidative Hypofractionated Radiotherapy for Oligometastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.08.003

Vancouver

Park J, Kang MK, Lee SY, Yoo SS, Choi SH, Park JY, et al. Consolidative Hypofractionated Radiotherapy for Oligometastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.08.003

BibTeX
@article{Park2026,
  author = {Park, Jongmoo and Kang, Min Kyu and Lee, Shin Yup and Yoo, Seung Soo and Choi, Sun Ha and Park, Jae Yong and Do, Young Woo and Lee, Eung Bae and Jeong, Shin Young and Kim, Moonsik and Bae, Bong Kyung},
  title = {Consolidative Hypofractionated Radiotherapy for Oligometastatic Non–Small-Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.08.003}
}
Kostenlos starten →